CJC-1295 + Ipamorelin Blend
GH OptimizationMaximized pulsatile GH release with minimal side effects via dual receptor stimulation.
GHRH + GHRP dual stimulation: CJC-1295 provides the GHRH pulse to prime the pituitary; Ipamorelin provides the selective GHRP pulse for GH release without cortisol or prolactin elevation.
For athletes, the primary value of CJC-1295 + Ipamorelin Blend lies in its ability to maximized pulsatile gh release with minimal side effects via dual receptor stimulation.. This mechanism is particularly relevant during high-volume training phases when tissue repair demand exceeds the body's natural recovery capacity.
Variable — onset typically within 2–8 weeks depending on protocol and individual response.
Individual response varies based on injury severity, training load, and baseline health markers.
Well tolerated. Minor injection site reactions possible. Avoid in active malignancy.
Always verify current WADA status with your sport's governing body before use in competition.
Svensson J, et al. J Clin Endocrinol Metab. 1997;82(10):3455-63.
Raun K, et al. Eur J Endocrinol. 1998;139(5):552-61.
Start a CJC-1295 + Ipamorelin Blend Protocol
Hatter Labs provides physician-supervised performance protocols with GMP-certified CJC-1295 + Ipamorelin Blend and comprehensive biomarker monitoring.
Get ProtocolStart Your Performance Protocol for CJC-1295 + Ipamorelin Blend
Hatter Labs provides physician-supervised performance protocols with GMP-certified compounds, biomarker testing, and personalized programs designed around your training goals.
HIPAA Compliant · GMP Certified · Physician Supervised